183 related articles for article (PubMed ID: 27258230)
41. Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome.
Chakrabarti LA; Boucherie C; Bugault F; Cumont MC; Roussillon C; Breton G; Patey O; Chêne G; Richert L; Lortholary O;
AIDS; 2014 Jul; 28(11):1593-602. PubMed ID: 24865974
[TBL] [Abstract][Full Text] [Related]
42. Low-level HIV viremia is associated with microbial translocation and inflammation.
Reus S; Portilla J; Sánchez-Payá J; Giner L; Francés R; Such J; Boix V; Merino E; Gimeno A
J Acquir Immune Defic Syndr; 2013 Feb; 62(2):129-34. PubMed ID: 23018379
[TBL] [Abstract][Full Text] [Related]
43. A CD4+ cell count <200 cells per cubic millimeter at 2 years after initiation of combination antiretroviral therapy is associated with increased mortality in HIV-infected individuals with viral suppression.
Loutfy MR; Genebat M; Moore D; Raboud J; Chan K; Antoniou T; Milan D; Shen A; Klein MB; Cooper C; Machouf N; Rourke SB; Rachlis A; Tsoukas C; Montaner JS; Walmsley SL; Smieja M; Bayoumi A; Mills E; Hogg RS;
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):451-9. PubMed ID: 21105259
[TBL] [Abstract][Full Text] [Related]
44. HIV disease is associated with increased biomarkers of endothelial dysfunction despite viral suppression on long-term antiretroviral therapy in Botswana.
Mosepele M; Mohammed T; Mupfumi L; Moyo S; Bennett K; Lockman S; Hemphill LC; Triant VA
Cardiovasc J Afr; 2018 May/Jun 23; 29(3):155-161. PubMed ID: 29771268
[TBL] [Abstract][Full Text] [Related]
45. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
Demeter LM; Hughes MD; Coombs RW; Jackson JB; Grimes JM; Bosch RJ; Fiscus SA; Spector SA; Squires KE; Fischl MA; Hammer SM
Ann Intern Med; 2001 Dec; 135(11):954-64. PubMed ID: 11730396
[TBL] [Abstract][Full Text] [Related]
46. Effect of Structured Physical Activity on Inflammation and Immune Activation Profile of Antiretroviral Therapy-Experienced Children Living With HIV.
Gopalan BP; Dias M; Arumugam K; D'Souza RR; Perumpil M; Kulkarni P; Ranga U; Shet A
Pediatr Exerc Sci; 2020 May; 32(2):73-80. PubMed ID: 31881531
[TBL] [Abstract][Full Text] [Related]
47. Increased systemic immune activation and inflammatory profile of long-term HIV-infected ART-controlled patients is related to personal factors, but not to markers of HIV infection severity.
Bastard JP; Fellahi S; Couffignal C; Raffi F; Gras G; Hardel L; Sobel A; Leport C; Fardet L; Capeau J;
J Antimicrob Chemother; 2015; 70(6):1816-24. PubMed ID: 25733587
[TBL] [Abstract][Full Text] [Related]
48. Risk factors for increased immune reconstitution in response to Mycobacterium tuberculosis antigens in tuberculosis HIV-infected, antiretroviral-naïve patients.
da Silva TP; Giacoia-Gripp CBW; Schmaltz CA; Sant'Anna FM; Saad MH; Matos JA; de Lima E Silva JCA; Rolla VC; Morgado MG
BMC Infect Dis; 2017 Sep; 17(1):606. PubMed ID: 28874142
[TBL] [Abstract][Full Text] [Related]
49. Association of inflammatory cytokines and endothelial adhesion molecules with immunological, virological, and cardiometabolic disease in HIV-infected individuals.
Lacerda HR; Falcão Mda C; de Albuquerque VM; Zírpoli JC; Miranda-Filho Dde B; de Albuquerque Mde F; Montarroyos U; Ximenes RA
J Interferon Cytokine Res; 2014 May; 34(5):385-93. PubMed ID: 24359573
[TBL] [Abstract][Full Text] [Related]
50. Disparities in Initiation of Combination Antiretroviral Treatment and in Virologic Suppression Among Patients in the HIV Outpatient Study, 2000-2013.
Novak RM; Hart RL; Chmiel JS; Brooks JT; Buchacz K;
J Acquir Immune Defic Syndr; 2015 Sep; 70(1):23-32. PubMed ID: 25886926
[TBL] [Abstract][Full Text] [Related]
51. Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients.
Dejesus E; Young B; Morales-Ramirez JO; Sloan L; Ward DJ; Flaherty JF; Ebrahimi R; Maa JF; Reilly K; Ecker J; McColl D; Seekins D; Farajallah A;
J Acquir Immune Defic Syndr; 2009 Jun; 51(2):163-74. PubMed ID: 19357529
[TBL] [Abstract][Full Text] [Related]
52. Short Intracellular HIV-1 Transcripts as Biomarkers of Residual Immune Activation in Patients on Antiretroviral Therapy.
Ishizaka A; Sato H; Nakamura H; Koga M; Kikuchi T; Hosoya N; Koibuchi T; Nomoto A; Kawana-Tachikawa A; Mizutani T
J Virol; 2016 Jun; 90(12):5665-5676. PubMed ID: 27030274
[TBL] [Abstract][Full Text] [Related]
53. Probiotics Reduce Inflammation in Antiretroviral Treated, HIV-Infected Individuals: Results of the "Probio-HIV" Clinical Trial.
d'Ettorre G; Ceccarelli G; Giustini N; Serafino S; Calantone N; De Girolamo G; Bianchi L; Bellelli V; Ascoli-Bartoli T; Marcellini S; Turriziani O; Brenchley JM; Vullo V
PLoS One; 2015; 10(9):e0137200. PubMed ID: 26376436
[TBL] [Abstract][Full Text] [Related]
54. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA.
Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC
AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544
[TBL] [Abstract][Full Text] [Related]
55. Continued Elevation of Interleukin-18 and Interferon-γ After Initiation of Antiretroviral Therapy and Clinical Failure in a Diverse Multicountry Human Immunodeficiency Virus Cohort.
Balagopal A; Gupte N; Shivakoti R; Cox AL; Yang WT; Berendes S; Mwelase N; Kanyama C; Pillay S; Samaneka W; Santos B; Poongulali S; Tripathy S; Riviere C; Lama JR; Cardoso SW; Sugandhavesa P; Semba RD; Hakim J; Hosseinipour MC; Kumarasamy N; Sanne I; Asmuth D; Campbell T; Bollinger RC; Gupta A
Open Forum Infect Dis; 2016 Sep; 3(3):ofw118. PubMed ID: 27800521
[No Abstract] [Full Text] [Related]
56. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
Nokta M; Rossero R; Loesch K; Pollard RB
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1633-8. PubMed ID: 9430255
[TBL] [Abstract][Full Text] [Related]
57. Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART).
Merlini E; Iannuzzi F; Calcagno A; Bai F; Trunfio M; d'Arminio Monforte A; Bonora S; Marchetti G
J Neurovirol; 2018 Dec; 24(6):679-694. PubMed ID: 29987585
[TBL] [Abstract][Full Text] [Related]
58. Daily low-dose subcutaneous interleukin-2 added to single- or dual-nucleoside therapy in HIV infection does not protect against CD4+ T-cell decline or improve other indices of immune function: results of a randomized controlled clinical trial (ACTG 248).
Vogler MA; Teppler H; Gelman R; Valentine F; Lederman MM; Pomerantz RJ; Pollard RB; Cherng DW; Gonzalez CJ; Squires KE; Frank I; Mildvan D; Mahon LF; Schock B;
J Acquir Immune Defic Syndr; 2004 May; 36(1):576-87. PubMed ID: 15097300
[TBL] [Abstract][Full Text] [Related]
59. CXCL13 as a Biomarker of Immune Activation During Early and Chronic HIV Infection.
Mehraj V; Ramendra R; Isnard S; Dupuy FP; Lebouché B; Costiniuk C; Thomas R; Szabo J; Baril JG; Trottier B; Coté P; LeBlanc R; Durand M; Chartrand-Lefebvre C; Kema I; Zhang Y; Finkelman M; Tremblay C; Routy JP
Front Immunol; 2019; 10():289. PubMed ID: 30846990
[No Abstract] [Full Text] [Related]
60. Long-term effectiveness of initiating non-nucleoside reverse transcriptase inhibitor- versus ritonavir-boosted protease inhibitor-based antiretroviral therapy: implications for first-line therapy choice in resource-limited settings.
Lima VD; Hull M; McVea D; Chau W; Harrigan PR; Montaner JS
J Int AIDS Soc; 2016; 19(1):20978. PubMed ID: 27499064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
